You are here

Article Text

Article menu
Download PDFPDF
Letters
Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice
  1. N Neven1,
  2. M Vis1,
  3. A E Voskuyl2,
  4. G J Wolbink1,
  5. M T Nurmohamed3,
  6. B A C Dijkmans2,
  7. W F Lems1
  1. 1Department of Rheumatology, Slotervaart Hospital, Amsterdam, The Netherlands
  2. 2Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
  3. 3Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands
  1. Correspondence to:
    Dr A E Voskuyl
    Department of Rheumatology 4A42, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; ae.voskuylvumc.nl

https://doi.org/10.1136/ard.2004.028597

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Infliximab is highly effective and relatively safe for the treatment of patients with rheumatoid arthritis (RA) in clinical trials.1–,5 This prospective cohort study was undertaken to determine adverse events, in particular, infections in patients with RA treated with infliximab in daily clinical practice.

    METHODS AND RESULTS

    We treated 168 patients with RA between 1 April 2000 and 1 October 2002, 82% female, with a median disease duration of 10 years (range 1–49). Inclusion criteria were 28 joint count Disease Activity Score (DAS28) of >3.5 and failure of two disease modifying antirheumatic drugs, including methotrexate. Patients with heart failure or with a malignancy 5 years before screening were excluded. After the alert about tuberculosis,6 patients starting with infliximab treatment were screened for that disease.

    All patients …

    View Full Text